INVIVOSCRIBE INC.

In News

System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows - Business Wire

Business Wire - Apr 15, 2026

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia - Nature

Nature - Nov 24, 2025

Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine - PR Newswire

PR Newswire - May 09, 2022

Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia - PR Newswire

PR Newswire - Jul 14, 2020

Cancer Biomarkers Market Report 2026-2032, By Product, Profiling Technology, and Geo - MarketsandMarkets

MarketsandMarkets - May 18, 2026

Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification - Business Wire

Business Wire - Mar 26, 2026

Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML - aap.com.au

aap.com.au - Oct 24, 2022

Novartis wins US approval of Rydapt for rare type of AML - BioPharma Dive

BioPharma Dive - May 01, 2017

Achondrogenesis Market Growth Analysis | CAGR of 4.8% - Market.us

Market.us - Sep 05, 2019

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay - Business Wire

Business Wire - Apr 21, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment